Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial
Cyclo-oxygenase (COX) is a family of enzymes regulating the conversion of arachidonic acid
to prostaglandins. COX-II is an inducible enzyme, which may be upregulated when there are
stimuli such as inflammation or hypergastrinaemia. Despite radical surgery, patients with
stomach cancer of advanced stages often have a poor prognosis. Reported survival in those
with diseases of stage IIIa or above is less than 40%. Methods to improve patients outcome
have been explored for decades with little success. In the light of current understanding on
the relation between COX-II and stomach cancer, selective COX-II inhibitor may be used as a
novel adjuvant therapy after gastrectomy to prevent recurrence of gastric carcinoma. The
advantages of COX-II inhibitors are being relatively non-toxic with minimal side effect.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Recurrence free survival and the quality of life score within the two years of study period
Enders K.W. Ng, MD
Principal Investigator
Chinese University of Hong Kong
Hong Kong: Department of Health
CRE-2001.463-T
NCT00164892
October 2004
Name | Location |
---|